Lexicon Pharmaceuticals
LXRX
113 hedge funds and large institutions have $204M invested in Lexicon Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 26 reducing their positions, and 22 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 26
20% more call options, than puts
Call options by funds: $293K | Put options by funds: $245K
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less funds holding
Funds holding: 115 → 113 (-2)
2.87% less ownership
Funds ownership: 100.86% → 97.99% (-2.9%)
54% less capital invested
Capital invested by funds: $445M → $204M (-$240M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.71M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.54M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.8M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$1.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$11.5M |
| 2 |
Millennium Management
New York
|
-$5.43M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$3.17M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.96M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.84M |
LXRX Hedge Fund Activity: Q1 2020 in Review
113 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2020, worth a combined $204M — down 54% from $445M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LXRX positions and 22 closed out — a net gain of 1 holder — while 36 added to existing stakes and 26 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $2.71M. The largest seller was Boxer Capital, exiting entirely with an estimated $11.5M sold.
- 113 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2020, down from 115 in Q4 2019.
- Funds reported $204M of Lexicon Pharmaceuticals stock for Q1 2020, down 54% quarter-over-quarter.
- 23 funds opened new Lexicon Pharmaceuticals positions in Q1 2020 and 22 closed out, a net change of +1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q1 2020 was Acadian Asset Management, an estimated $2.71M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2020 was Boxer Capital, an estimated $11.5M sold.
Based on aggregated 13F filings for Q1 2020.